Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK104 in Neoadjuvant Treatment of Cervical Cancer
NCT05227651Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Feb 2023
- Primary completion
- Sep 2024
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in Cervical Cancer (CC), sponsored by Akeso, Inc.. Started Feb 2023; status: completed.
02
Drugs
cadonilimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT05227651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05227651.